A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Recombinant Botulinum Toxin Type a (JHM03) in Adult Patients with Upper Limb Spasticity.

This article provides information about a newly launched clinical trial, NCT06584240, which aims to evaluate the safety and efficacy of a recombinant botulinum toxin type A (JHM03) in adult patients with upper limb spasticity. The study will compare the effectiveness and safety of JHM03 with a placebo in this patient population. The trial is currently in the recruitment phase and is expected to be completed by February 2026. The article also includes details about the trial's design, eligibility criteria, and contact information for the primary investigator. [Extracted from the article]